Peginterferon Alfa-2A
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Peginterferon Alfa-2A
- Peginterferon alfa-2a: From Chronic Hepatitis C and B to Hepatitis B Virus Infection
Peginterferon alfa-2a: From Chronic Hepatitis C and B to Hepatitis B Virus Infection
One-Sentence Summary
Peginterferon alfa-2a is a long-acting interferon originally used to treat chronic hepatitis C and chronic hepatitis B. The TxGNN model predicts it may be effective for hepatitis B virus infection, with 20 clinical trials and 20 publications currently supporting this direction. Note that hepatitis B is already listed among the drug's original indications, so this result confirms an existing use rather than a true repurposing discovery.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic hepatitis C virus infection; chronic hepatitis B virus infection (the Singapore licence records contain no indication text) |
| Predicted New Indication | Hepatitis B virus infection |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, peginterferon alfa-2a is a pegylated interferon with immunomodulatory and antiviral effects. Its efficacy in chronic hepatitis C and chronic hepatitis B is established, and it is mechanistically applicable to hepatitis B virus infection.
The literature describes induction of interferon-stimulated genes and enhanced HBV-specific T-cell responses as the basis for its activity against HBV. Because hepatitis B is already among the drug's original indications, the high prediction score (rank 1323 of the model's ranking) is consistent with an established use. The prediction therefore mostly validates the model rather than pointing to a new therapeutic area.
Other predictions (hepatitis E, hepatitis A, tick-borne flavivirus diseases, and cardiac conditions) have weak or no supporting evidence and are not the focus of this report. Hepatitis E has only a plausible rationale based on off-label use, and the trials linked to it are actually hepatitis B studies. The cardiac and congenital predictions have no plausible mechanism and are probably artifacts of the knowledge graph.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02604823 | Phase 4 | Completed | 307 | Efficacy and safety of peginterferon alfa-2a for 48 weeks in HBeAg-positive chronic hepatitis B (naive, interferon- or lamivudine-pretreated) |
| NCT00661076 | Phase 3 | Completed | 10 | Randomized comparison of PEGASYS plus adefovir versus PEGASYS alone in HBeAg-negative chronic hepatitis B; very small enrollment |
| NCT00614471 | Phase 4 | Completed | 219 | Randomized comparison of PEGASYS alone or combined with entecavir in HBeAg-positive treatment-naive patients |
| NCT02474316 | Phase 4 | Unknown | 366 | Switching HBeAg-positive patients on nucleoside analogues to peginterferon plus NA versus entecavir alone |
| NCT02560649 | Phase 4 | Unknown | 324 | Response-guided add-on of peginterferon alfa-2a in NUC-experienced patients to improve HBsAg clearance |
| NCT03181113 | N/A | Completed | 473 | Long-term follow-up cohort of HBeAg-positive patients previously given peginterferon alfa |
| NCT02097004 | Phase 4 | Completed | 111 | Therapeutic vaccination plus peginterferon for HBsAg seroclearance after entecavir response |
| NCT03084250 | Phase 4 | Unknown | 150 | Peginterferon alfa-2a added to NA in cirrhotic patients at high risk of hepatocellular carcinoma |
| NCT01906580 | Phase 4 | Unknown | 105 | Combination or sequential peginterferon alfa-2a and entecavir in HBeAg-positive patients |
| NCT02570191 | Phase 4 | Completed | 60 | Open-label study of efficacy and safety in HBeAg-negative chronic hepatitis B |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15987917 | 2005 | RCT | N Engl J Med | Peginterferon alfa-2a with or without lamivudine compared with lamivudine alone in HBeAg-positive chronic hepatitis B |
| 30549279 | 2019 | RCT | Hepatology | Entecavir plus peginterferon alfa-2a in adults with HBeAg-positive immune-tolerant chronic HBV infection |
| 26299874 | 2016 | Meta-analysis | Clin Res Hepatol Gastroenterol | Extended versus standard duration of peginterferon alfa-2a monotherapy in chronic hepatitis B |
| 30865588 | 2019 | Meta-analysis | Antivir Ther | Individual-participant-data analysis to define peginterferon alfa-2a stopping rules |
| 22045673 | 2011 | Randomized trial | Hepatology | Shorter durations and lower doses linked to lower HBeAg seroconversion in genotypes B or C |
| 33720089 | 2021 | Randomized trial | J Pediatr Gastroenterol Nutr | Peginterferon alfa-2a plus lamivudine or entecavir in children with immune-tolerant chronic hepatitis B |
| 26700861 | 2015 | Randomized trial | Virol J | Long-term effects of peginterferon alfa-2a in Japanese patients with chronic hepatitis B |
| 30318613 | 2019 | Clinical trial | Hepatology | Entecavir plus peginterferon alfa-2a in children with HBeAg-positive immune-tolerant infection |
| 32548156 | 2020 | Cohort | World J Clin Cases | Cytokine levels predict virological response during peginterferon alfa-2a therapy |
| 26188762 | 2016 | Review | J Formos Med Assoc | Perspectives on dual HBV/HCV infection in Taiwan, including peginterferon and ribavirin combination therapy |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12313P | PEGASYS Pre-filled Syringe for Injection 180 mcg/0.5 ml | Injection | Not recorded in the licence data |
| SIN12314P | PEGASYS Pre-filled Syringe for Injection 135 mcg/0.5 ml | Injection | Not recorded in the licence data |
Both licences are valid, single-ingredient products held by F. Hoffmann-La Roche Ltd.
Safety Considerations
Drug Interactions: The interaction screening returned 100 potential interactions. Examples of Major-level interactions include:
- Bupropion
- Deferiprone
- Iopamidol
- Iohexol
- Samarium (153Sm) lexidronam
- Eltrombopag
Examples of Moderate-level interactions include metronidazole, tinidazole, warfarin, dicoumarol, simvastatin, rosuvastatin, naltrexone, chloroquine, and pegvaliase.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for these safety details. The literature also notes that interferon therapy is associated with neuropsychiatric effects (such as depression) and cardiac adverse events, so these should be monitored.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple randomized and controlled studies, including a large NEJM trial and several Phase 3/4 trials, support peginterferon alfa-2a in chronic hepatitis B, and the drug is already marketed in Singapore. However, this is a confirmation of an existing indication, not a new repurposing opportunity, and several of the listed trials are small or have unknown status.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA to complete the safety review
- Mechanism of action data
- The approved indication text for the two Singapore licences, to confirm whether hepatitis B is on the local label
- Application of stopping rules (PMID 30865588) and monitoring for interferon-related adverse events, noting that HBeAg status, genotype and baseline HBsAg influence response
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.